ESTRO 2024 - Abstract Book

S1032

Clinical - Gynaecology

ESTRO 2024

associated with decreased distant metastasis-free survival (DMFS) and overall survival (OS) rates in both univariate and multivariate analyses. Higher hemoglobin (Hb) levels (≥ 12 g/dL) were linked to improved local control (LC), disease-free survival (DFS), and OS. Furthermore, FIGO stage III-IV was associated with worse LC, DMFS, DFS, and OS in univariate analysis, while FIGO stage I-II displayed more favorable prognoses, which was confirmed in multivariable analysis. Despite an adverse correlation between lymph node metastases and DMFS in univariate analysis, this association was not supported by multivariate analysis. Tumor diameter, histological type, and overall treatment duration showed no significant correlations with the examined outcomes. Cumulative doses of concurrent CRT plus BRT were consistently linked to improved OS. BMI was correlated with better DFS in multivariate analysis. Notably, the presence of sarcopenic obesity (SO) revealed significant adverse correlations with LC, DFS, and OS in both univariate and multivariate analyses.

Conclusion: